The French ANSM has confirmed that flower will not be included in its upcoming generalised medical cannabis framework.
While not wholly unexpected, the abrupt nature and failure of the ANSM to provide any viable alternative to patients currently dependent on cannabis flower has sparked outrage.
The confirmation will also come as a disappointment to French cannabis businesses, which will be distinctly aware of the dominance of medical cannabis flower in markets across Europe.
Augur Associates gives more insight in this article from Business Of Cannabis.